Approaches to improving the kinetics of adenovirus-delivered genes and gene products.

[1]  Florian Kreppel,et al.  Long-Term Transgene Expression in Proliferating Cells Mediated by Episomally Maintained High-Capacity Adenovirus Vectors , 2004, Journal of Virology.

[2]  H. Mizuguchi,et al.  Reduction of Natural Adenovirus Tropism to Mouse Liverby Fiber-Shaft Exchange in Combination with both CAR- andαv Integrin-BindingAblation , 2003, Journal of Virology.

[3]  G. Nemerow,et al.  Transductional and transcriptional targeting of cancer cells using genetically engineered viral vectors. , 2003, Cancer letters.

[4]  H. Mizuguchi,et al.  A soluble CAR‐SCF fusion protein improves adenoviral vector‐mediated gene transferto c‐Kit‐positive hematopoietic cells , 2003, The journal of gene medicine.

[5]  H. Mizuguchi,et al.  Characterization of in vitro and in vivo gene transfer properties of adenovirus serotype 35 vector. , 2003, Molecular therapy : the journal of the American Society of Gene Therapy.

[6]  P. Robbins,et al.  Human adenovirus type 35: nucleotide sequence and vector development , 2003, Gene Therapy.

[7]  A. Gaggar,et al.  CD46 is a cellular receptor for group B adenoviruses , 2003, Nature Medicine.

[8]  Cameron S. Osborne,et al.  LMO2-Associated Clonal T Cell Proliferation in Two Patients after Gene Therapy for SCID-X1 , 2003, Science.

[9]  M. Kay,et al.  A gene-deleted adenoviral vector results in phenotypic correction of canine hemophilia B without liver toxicity or thrombocytopenia. , 2003, Blood.

[10]  P. Lowenstein,et al.  Adenovirus expression of IL-1 and NF-kappaB inhibitors does not inhibit acute adenoviral-induced brain inflammation, but delays immune system-mediated elimination of transgene expression. , 2003, Molecular therapy : the journal of the American Society of Gene Therapy.

[11]  J. Atkinson,et al.  Adenovirus Type 11 Uses CD46 as a Cellular Receptor , 2003, Journal of Virology.

[12]  S. Kostense,et al.  Replication-Deficient Human Adenovirus Type 35 Vectors for Gene Transfer and Vaccination: Efficient Human Cell Infection and Bypass of Preexisting Adenovirus Immunity , 2003, Journal of Virology.

[13]  K. Ozawa,et al.  Positive and negative effects of adeno-associated virus Rep on AAVS1-targeted integration. , 2003, The Journal of general virology.

[14]  M. Kaleko,et al.  Development of adenovirus serotype 35 as a gene transfer vector. , 2003, Virology.

[15]  Theresa A. Storm,et al.  AAV serotype 2 vectors preferentially integrate into active genes in mice , 2003, Nature Genetics.

[16]  T. Mayumi,et al.  Woodchuck hepatitis virus post-transcriptional regulation element enhances transgene expression from adenovirus vectors. , 2003, Biochimica et biophysica acta.

[17]  H. Mizuguchi,et al.  Efficient gene transfer into human CD34+ cells by an adenovirus type 35 vector , 2003, Gene Therapy.

[18]  Qiang Liu,et al.  Molecular basis of the inflammatory response to adenovirus vectors , 2003, Gene Therapy.

[19]  N. Chirmule,et al.  Immunity to adenovirus and adeno-associated viral vectors: implications for gene therapy , 2003, Gene Therapy.

[20]  J. Bromberg,et al.  Adaptive and innate immune responses to gene transfer vectors: role of cytokines and chemokines in vector function , 2003, Gene Therapy.

[21]  G. Nemerow,et al.  Adenovirus serotype 5 fiber shaft influences in vivo gene transfer in mice. , 2003, Human gene therapy.

[22]  M. Rots,et al.  A mosaic adenovirus possessing serotype Ad5 and serotype Ad3 knobs exhibits expanded tropism. , 2003, Virology.

[23]  Stefan Fischer,et al.  Impact of human interleukin-10 on vector-induced inflammation and early graft function in rat lung transplantation. , 2003, American journal of respiratory cell and molecular biology.

[24]  Yasuo Yoshioka,et al.  Site-specific PEGylation of a lysine-deficient TNF-α with full bioactivity , 2003, Nature Biotechnology.

[25]  H. Mizuguchi,et al.  Generation of fiber‐modified adenovirus vectors containing heterologous peptides in both the HI loop and C terminus of the fiber knob , 2003, The journal of gene medicine.

[26]  K. Kawamoto,et al.  A Glucocorticoid Reduces Adverse Effects of Adenovirus Vectors in the Cochlea , 2003, Audiology and Neurotology.

[27]  S. Kochanek,et al.  Therapeutic factor VIII levels and negligible toxicity in mouse and dog models of hemophilia A following gene therapy with high-capacity adenoviral vectors. , 2003, Blood.

[28]  H. Hamada,et al.  Reduction of Natural Adenovirus Tropism to the Liver by both Ablation of Fiber-Coxsackievirus and Adenovirus Receptor Interaction and Use of Replaceable Short Fiber , 2003, Journal of Virology.

[29]  D. Kayda,et al.  Optimization of the generation and propagation of gutless adenoviral vectors. , 2003, Human gene therapy.

[30]  E. Marshall.  Second Child in French Trial Is Found to Have Leukemia , 2003, Science.

[31]  A. Segerman,et al.  There Are Two Different Species B Adenovirus Receptors: sBAR, Common to Species B1 and B2 Adenoviruses, and sB2AR, Exclusively Used by Species B2 Adenoviruses , 2003, Journal of Virology.

[32]  Jianghuai Wang,et al.  Integration efficiency of a hybrid adenoretroviral vector. , 2003, Biochemical and biophysical research communications.

[33]  M. Perricaudet,et al.  Genetic manipulations of adenovirus type 5 fiber resulting in liver tropism attenuation , 2003, Gene Therapy.

[34]  Erika Check,et al.  Gene therapy: A tragic setback , 2002, Nature.

[35]  James M. Wilson,et al.  PEGylation of E1-deleted adenovirus vectors allows significant gene expression on readministration to liver. , 2002, Human gene therapy.

[36]  M. Mizuno,et al.  Cationic liposomes conjugation to recombinant adenoviral vectors containing herpes simplex virus thymidine kinase gene followed by ganciclovir treatment reduces viral antigenicity and maintains antitumor activity in mouse experimental glioma models , 2002, Cancer Gene Therapy.

[37]  M. Kay,et al.  Transposition from a gutless adeno-transposon vector stabilizes transgene expression in vivo , 2002, Nature Biotechnology.

[38]  D. Curiel,et al.  Dual targeting of adenoviral vectors at the levels of transduction and transcription enhances the specificity of gene expression in cancer cells. , 2002, Molecular therapy : the journal of the American Society of Gene Therapy.

[39]  M. Rollence,et al.  In vivo hepatic adenoviral gene delivery occurs independently of the coxsackievirus-adenovirus receptor. , 2002, Molecular therapy : the journal of the American Society of Gene Therapy.

[40]  H. Mizuguchi,et al.  CAR- or αv integrin-binding ablated adenovirus vectors, but not fiber-modified vectors containing RGD peptide, do not change the systemic gene transfer properties in mice , 2002, Gene Therapy.

[41]  M. Kay,et al.  A new adenoviral helper-dependent vector results in long-term therapeutic levels of human coagulation factor IX at low doses in vivo. , 2002, Blood.

[42]  M. Goldberg,et al.  Correction of the nonlinear dose response improves the viability of adenoviral vectors for gene therapy of Fabry disease. , 2002, Human gene therapy.

[43]  T. Mayumi,et al.  Strength evaluation of transcriptional regulatory elements for transgene expression by adenovirus vector. , 2002, Journal of controlled release : official journal of the Controlled Release Society.

[44]  J. Douglas,et al.  Targeted adenoviral vectors , 2002 .

[45]  K. Mitani,et al.  Adenovirus as an integrating vector. , 2002, Current gene therapy.

[46]  S. Keshavjee,et al.  Transplant immunosuppression enhances efficiency of adenoviral-mediated gene retransfection: inhibition of interferon-gamma and immunoglobin G. , 2002, The Annals of thoracic surgery.

[47]  H. Mizuguchi,et al.  Enhanced antitumor effect and reduced vector dissemination with fiber-modified adenovirus vectors expressing herpes simplex virus thymidine kinase , 2002, Cancer Gene Therapy.

[48]  J. Isner.  Myocardial gene therapy , 2002, Nature.

[49]  W. F. Anderson.  Assessment of adenoviral vector safety and toxicity: Report of the National Institutes of Health Recombinant DNA Advisory Committee , 2002 .

[50]  A. Beaudet,et al.  Lethal toxicity, severe endothelial injury, and a threshold effect with high doses of an adenoviral vector in baboons. , 2002, Human gene therapy.

[51]  D. Kayda,et al.  Sustained human factor VIII expression in hemophilia A mice following systemic delivery of a gutless adenoviral vector. , 2002, Molecular therapy : the journal of the American Society of Gene Therapy.

[52]  R. M. Burnett,et al.  Replication-Defective Vector Based on a Chimpanzee Adenovirus , 2001, Journal of Virology.

[53]  I. Kovesdi,et al.  Reducing the Native Tropism of Adenovirus Vectors Requires Removal of both CAR and Integrin Interactions , 2001, Journal of Virology.

[54]  G. Nemerow,et al.  Ablating adenovirus type 5 fiber-CAR binding and HI loop insertion of the SIGYPLP peptide generate an endothelial cell-selective adenovirus. , 2001, Molecular therapy : the journal of the American Society of Gene Therapy.

[55]  H. Mizuguchi,et al.  Efficient gene transfer by fiber-mutant adenoviral vectors containing RGD peptide. , 2001, Biochimica et biophysica acta.

[56]  M. Dewhirst,et al.  Systemic vector leakage and transgene expression by intratumorally injected recombinant adenovirus vectors. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

[57]  T. Mayumi,et al.  Efficient antigen gene transduction using Arg-Gly-Asp fiber-mutant adenovirus vectors can potentiate antitumor vaccine efficacy and maturation of murine dendritic cells. , 2001, Cancer research.

[58]  In-Hoo Kim,et al.  Lifetime correction of genetic deficiency in mice with a single injection of helper-dependent adenoviral vector , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[59]  S. Kochanek,et al.  High-capacity 'gutless' adenoviral vectors. , 2001, Current opinion in molecular therapeutics.

[60]  A. Herrmann,et al.  Targeting of high-capacity adenoviral vectors. , 2001, Human gene therapy.

[61]  M. Chilosi,et al.  Heparan Sulfate Glycosaminoglycans Are Receptors Sufficient To Mediate the Initial Binding of Adenovirus Types 2 and 5 , 2001, Journal of Virology.

[62]  M. Kolb,et al.  Budesonide enhances repeated gene transfer and expression in the lung with adenoviral vectors. , 2001, American journal of respiratory and critical care medicine.

[63]  R. Alemany,et al.  CAR-binding ablation does not change biodistribution and toxicity of adenoviral vectors , 2001, Gene Therapy.

[64]  D. Curiel,et al.  Combined transductional and transcriptional targeting improves the specificity of transgene expression in vivo , 2001, Nature Biotechnology.

[65]  J. Ellis,et al.  Silencing of gene expression: implications for design of retrovirus vectors , 2001, Reviews in medical virology.

[66]  G. Stamatoyannopoulos,et al.  A capsid-modified adenovirus vector devoid of all viral genes: assessment of transduction and toxicity in human hematopoietic cells. , 2001, Molecular therapy : the journal of the American Society of Gene Therapy.

[67]  G. Nemerow,et al.  Integrin αvβ1 Is an Adenovirus Coreceptor , 2001, Journal of Virology.

[68]  R. Kontermann,et al.  Targeting of adenovirus to endothelial cells by a bispecific single-chain diabody directed against the adenovirus fiber knob domain and human endoglin (CD105). , 2001, Molecular therapy : the journal of the American Society of Gene Therapy.

[69]  B. Delmas,et al.  Construction of Avian Adenovirus CELO Recombinants in Cosmids , 2001, Journal of Virology.

[70]  James M. Wilson,et al.  “Stealth” Adenoviruses Blunt Cell-Mediated and Humoral Immune Responses against the Virus and Allow for Significant Gene Expression upon Readministration in the Lung , 2001, Journal of Virology.

[71]  J. Wilson,et al.  Acute cytokine response to systemic adenoviral vectors in mice is mediated by dendritic cells and macrophages. , 2001, Molecular therapy : the journal of the American Society of Gene Therapy.

[72]  J. Wilson,et al.  Activation of innate immunity in nonhuman primates following intraportal administration of adenoviral vectors. , 2001, Molecular therapy : the journal of the American Society of Gene Therapy.

[73]  P. Quax,et al.  Improved Adenovirus Vectors for Infection of Cardiovascular Tissues , 2001, Journal of Virology.

[74]  D. Curiel,et al.  Fiber knob modifications overcome low, heterogeneous expression of the coxsackievirus-adenovirus receptor that limits adenovirus gene transfer and oncolysis for human rhabdomyosarcoma cells. , 2001, Cancer research.

[75]  T. Mayumi,et al.  Efficient gene delivery into dendritic cells by fiber-mutant adenovirus vectors. , 2001, Biochemical and biophysical research communications.

[76]  D. Curiel,et al.  Efficient Gene Transduction by RGB‐fiber Modified Recombinant Adenovirus into Dendritic Cells , 2001, Japanese journal of cancer research : Gann.

[77]  P. Goossens,et al.  Infection efficiency of type 5 adenoviral vectors in synovial tissue can be enhanced with a type 16 fiber. , 2001, Arthritis and rheumatism.

[78]  M. Kaleko,et al.  Generation and characterization of E1/E2a/E3/E4-deficient adenoviral vectors encoding human factor VIII. , 2001, Molecular therapy : the journal of the American Society of Gene Therapy.

[79]  J. Grill,et al.  Combined targeting of adenoviruses to integrins and epidermal growth factor receptors increases gene transfer into primary glioma cells and spheroids. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

[80]  T. Sawamura,et al.  Identification of Peptides That Target the Endothelial Cell–Specific LOX-1 Receptor , 2001, Hypertension.

[81]  D. Curiel,et al.  Selective transduction of murine myelomonocytic leukemia cells (WEHI-3B) with regular and RGD-adenoviral vectors. , 2001, Molecular therapy : the journal of the American Society of Gene Therapy.

[82]  P. Lowenstein,et al.  Acute direct adenoviral vector cytotoxicity and chronic, but not acute, inflammatory responses correlate with decreased vector-mediated transgene expression in the brain. , 2001, Molecular therapy : the journal of the American Society of Gene Therapy.

[83]  S. Fawell,et al.  Sequestration of adenoviral vector by Kupffer cells leads to a nonlinear dose response of transduction in liver. , 2001, Molecular therapy : the journal of the American Society of Gene Therapy.

[84]  S. Cusack,et al.  Influence of adenoviral fiber mutations on viral encapsidation, infectivity and in vivo tropism , 2001, Gene Therapy.

[85]  D. Curiel,et al.  A targetable, injectable adenoviral vector for selective gene delivery to pulmonary endothelium in vivo. , 2000, Molecular therapy : the journal of the American Society of Gene Therapy.

[86]  A. Lieber,et al.  Dependence of Adenovirus Infectivity on Length of the Fiber Shaft Domain , 2000, Journal of Virology.

[87]  R. Alemany,et al.  Blood clearance rates of adenovirus type 5 in mice. , 2000, The Journal of general virology.

[88]  Inder M. Verma,et al.  Gene therapy: trials and tribulations , 2000, Nature Reviews Genetics.

[89]  P. Lowenstein,et al.  Strong promoters are the key to highly efficient, noninflammatory and noncytotoxic adenoviral-mediated transgene delivery into the brain in vivo. , 2000, Molecular therapy : the journal of the American Society of Gene Therapy.

[90]  M. Weitzman,et al.  Molecular adaptors for vascular-targeted adenoviral gene delivery. , 2000, Human gene therapy.

[91]  J. Bergelson,et al.  The dual impact of coxsackie and adenovirus receptor expression on human prostate cancer gene therapy. , 2000, Cancer research.

[92]  J. Wilson,et al.  Development of a rapid method for the PEGylation of adenoviruses with enhanced transduction and improved stability under harsh storage conditions. , 2000, Human gene therapy.

[93]  D. Curiel,et al.  Ectodomain of Coxsackievirus and Adenovirus Receptor Genetically Fused to Epidermal Growth Factor Mediates Adenovirus Targeting to Epidermal Growth Factor Receptor-Positive Cells , 2000, Journal of Virology.

[94]  S. J. White,et al.  Selective targeting of gene transfer to vascular endothelial cells by use of peptides isolated by phage display. , 2000, Circulation.

[95]  C. Balagué,et al.  Replicative adenoviruses for cancer therapy , 2000, Nature Biotechnology.

[96]  S. Moffatt,et al.  Circumvention of vector-specific neutralizing antibody response by alternating use of human and non-human adenoviruses: implications in gene therapy. , 2000, Virology.

[97]  J. Grill,et al.  Targeting of adenoviral vectors through a bispecific single-chain antibody , 2000, Cancer Gene Therapy.

[98]  M. Mizuno,et al.  Transduction efficiency of adenoviral vectors into human glioma cells increased by association with cationic liposomes. , 2000, Neurologia medico-chirurgica.

[99]  F. Deist,et al.  Gene therapy of human severe combined immunodeficiency (SCID)-X1 disease. , 2000, Science.

[100]  M. Mizuno,et al.  Cationic Liposome Conjugation to Recombinant Adenoviral Vector Reduces Viral Antigenicity , 2000, Japanese journal of cancer research : Gann.

[101]  M. Perricaudet,et al.  Stable transduction of actively dividing cells via a novel adenoviral/episomal vector. , 2000, Molecular therapy : the journal of the American Society of Gene Therapy.

[102]  G. Stamatoyannopoulos,et al.  Efficient Gene Transfer into Human CD34+ Cells by a Retargeted Adenovirus Vector , 2000, Journal of Virology.

[103]  O. Danos,et al.  Canine Adenovirus Vectors: an Alternative for Adenovirus-Mediated Gene Transfer , 2000, Journal of Virology.

[104]  G. Pierce,et al.  Fibroblast growth factor 2-retargeted adenoviral vectors exhibit a modified biolocalization pattern and display reduced toxicity relative to native adenoviral vectors. , 2000, Human gene therapy.

[105]  N. Fairweather,et al.  Retargeting of adenoviral vectors to neurons using the HC fragment of tetanus toxin , 2000, Gene Therapy.

[106]  E Marshall,et al.  Gene Therapy Death Prompts Review of Adenovirus Vector , 1999, Science.

[107]  L. Babiuk,et al.  Replication-Defective Bovine Adenovirus Type 3 as an Expression Vector , 1999, Journal of Virology.

[108]  M. Kay,et al.  Integrating Adenovirus–Adeno-Associated Virus Hybrid Vectors Devoid of All Viral Genes , 1999, Journal of Virology.

[109]  A. Beaudet,et al.  Administration of helper-dependent adenoviral vectors and sequential delivery of different vector serotype for long-term liver-directed gene transfer in baboons. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[110]  G. Pierce,et al.  FGF2-targeted adenoviral vectors for systemic and local disease. , 1999, Current opinion in molecular therapeutics.

[111]  A. Houtsmuller,et al.  Expression of Coxsackie adenovirus receptor and alphav-integrin does not correlate with adenovector targeting in vivo indicating anatomical vector barriers , 1999, Gene Therapy.

[112]  K. Kasono,et al.  Selective gene delivery to head and neck cancer cells via an integrin targeted adenoviral vector. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

[113]  D. Curiel,et al.  An advanced generation of adenoviral vectors selectively enhances gene transfer for ovarian cancer gene therapy approaches. , 1999, Gynecologic oncology.

[114]  C. Miller,et al.  Retargeting to EGFR enhances adenovirus infection efficiency of squamous cell carcinoma. , 1999, Archives of otolaryngology--head & neck surgery.

[115]  K. Spindler,et al.  Mouse adenovirus (MAV-1) expression in primary human endothelial cells and generation of a full-length infectious plasmid , 1999, Gene Therapy.

[116]  T. Curiel,et al.  Maturation of dendritic cells accompanies high-efficiency gene transfer by a CD40-targeted adenoviral vector. , 1999, Journal of immunology.

[117]  D. Curiel,et al.  Fibroblast growth factor 2 retargeted adenovirus has redirected cellular tropism: evidence for reduced toxicity and enhanced antitumor activity in mice. , 1999, Cancer research.

[118]  M. Kay,et al.  Implication of Interfering Antibody Formation and Apoptosis as Two Different Mechanisms Leading to Variable Duration of Adenovirus-Mediated Transgene Expression in Immune-Competent Mice , 1999, Journal of Virology.

[119]  Alan E. Smith,et al.  PEGylation of adenovirus with retention of infectivity and protection from neutralizing antibody in vitro and in vivo. , 1999, Human gene therapy.

[120]  J. Isner,et al.  Angiogenesis and vasculogenesis as therapeutic strategies for postnatal neovascularization. , 1999, The Journal of clinical investigation.

[121]  G. Pari,et al.  Expression of the primary coxsackie and adenovirus receptor is downregulated during skeletal muscle maturation and limits the efficacy of adenovirus-mediated gene delivery to muscle cells. , 1999, Human gene therapy.

[122]  R. Cortese,et al.  Site-specific integration mediated by a hybrid adenovirus/adeno-associated virus vector. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[123]  R. Crystal,et al.  CAR-dependent and CAR-independent pathways of adenovirus vector-mediated gene transfer and expression in human fibroblasts. , 1999, The Journal of clinical investigation.

[124]  A. Sagalowsky,et al.  Loss of adenoviral receptor expression in human bladder cancer cells: a potential impact on the efficacy of gene therapy. , 1999, Cancer research.

[125]  C. Miller,et al.  Differential susceptibility of primary and established human glioma cells to adenovirus infection: targeting via the epidermal growth factor receptor achieves fiber receptor-independent gene transfer. , 1998, Cancer Research.

[126]  J. Gall,et al.  Construction and Characterization of Hexon-Chimeric Adenoviruses: Specification of Adenovirus Serotype , 1998, Journal of Virology.

[127]  M. Kay,et al.  Inhibition of NF-κB Activation in Combination with Bcl-2 Expression Allows for Persistence of First-Generation Adenovirus Vectors in the Mouse Liver , 1998, Journal of Virology.

[128]  D. Brough,et al.  The Coxsackievirus-Adenovirus Receptor Protein Can Function as a Cellular Attachment Protein for Adenovirus Serotypes from Subgroups A, C, D, E, and F , 1998, Journal of Virology.

[129]  G F Pierce,et al.  Basic fibroblast growth factor enhancement of adenovirus-mediated delivery of the herpes simplex virus thymidine kinase gene results in augmented therapeutic benefit in a murine model of ovarian cancer. , 1998, Clinical cancer research : an official journal of the American Association for Cancer Research.

[130]  A. van der Eb,et al.  New helper cells and matched early region 1-deleted adenovirus vectors prevent generation of replication-competent adenoviruses. , 1998, Human gene therapy.

[131]  M. Kaleko,et al.  Circumvention of Immunity to the Adenovirus Major Coat Protein Hexon , 1998, Journal of Virology.

[132]  A. Beaudet,et al.  Toxicological comparison of E2a-deleted and first-generation adenoviral vectors expressing alpha1-antitrypsin after systemic delivery. , 1998, Human gene therapy.

[133]  D. Fisher,et al.  PEGylation of cytokines and other therapeutic proteins and peptides: the importance of biological optimisation of coupling techniques. , 1998, International journal of hematology.

[134]  S. Randell,et al.  Limited Entry of Adenovirus Vectors into Well-Differentiated Airway Epithelium Is Responsible for Inefficient Gene Transfer , 1998, Journal of Virology.

[135]  James M. Wilson,et al.  Adenovirus-mediated herpes simplex virus thymidine kinase/ganciclovir gene therapy in patients with localized malignancy: results of a phase I clinical trial in malignant mesothelioma. , 1998, Human gene therapy.

[136]  M. Lusky,et al.  In Vitro and In Vivo Biology of Recombinant Adenovirus Vectors with E1, E1/E2A, or E1/E4 Deleted , 1998, Journal of Virology.

[137]  L. Turka,et al.  Blunting of immune responses to adenoviral vectors in mouse liver and lung with CTLA4Ig , 1998, Gene Therapy.

[138]  C. Miller,et al.  Characterization of an Adenovirus Vector Containing a Heterologous Peptide Epitope in the HI Loop of the Fiber Knob , 1998, Journal of Virology.

[139]  S. Efstathiou,et al.  High adenoviral loads stimulate NFκB-dependent gene expression in human vascular smooth muscle cells , 1998, Gene Therapy.

[140]  R. Plasterk,et al.  Molecular Reconstruction of Sleeping Beauty , a Tc1-like Transposon from Fish, and Its Transposition in Human Cells , 1997, Cell.

[141]  D. Brough,et al.  Increased in vitro and in vivo gene transfer by adenovirus vectors containing chimeric fiber proteins , 1997, Journal of virology.

[142]  M. Kay,et al.  The role of Kupffer cell activation and viral gene expression in early liver toxicity after infusion of recombinant adenovirus vectors , 1997, Journal of virology.

[143]  R. Hawkins,et al.  The ‘adenobody’ approach to viral targeting: specific and enhanced adenoviral gene delivery , 1997, Gene Therapy.

[144]  R. Crystal,et al.  Tumor necrosis factor α plays a central role in immune-mediated clearance of adenoviral vectors , 1997 .

[145]  J. Zabner,et al.  Lack of high affinity fiber receptor activity explains the resistance of ciliated airway epithelia to adenovirus infection. , 1997, The Journal of clinical investigation.

[146]  J. Marshall,et al.  Integrin alpha5beta1-mediated adenovirus infection is enhanced by the integrin-activating antibody TS2/16 , 1997, Journal of virology.

[147]  M. Rollence,et al.  Selective targeting of human cells by a chimeric adenovirus vector containing a modified fiber protein , 1997, Journal of virology.

[148]  Guido Kroemer,et al.  The proto-oncogene Bcl-2 and its role in regulating apoptosis , 1997, Nature Medicine.

[149]  A. Gown,et al.  Transient immunomodulation with anti-CD40 ligand antibody and CTLA4Ig enhances persistence and secondary adenovirus-mediated gene transfer into mouse liver. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[150]  D. Curiel,et al.  Targeted gene delivery to Kaposi's sarcoma cells via the fibroblast growth factor receptor. , 1997, Cancer research.

[151]  L. Philipson,et al.  HCAR and MCAR: the human and mouse cellular receptors for subgroup C adenoviruses and group B coxsackieviruses. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[152]  B. Davidson,et al.  Complexes of Adenovirus with Polycationic Polymers and Cationic Lipids Increase the Efficiency of Gene Transfer in Vitro and in Vivo* , 1997, The Journal of Biological Chemistry.

[153]  J. Bergelson,et al.  Isolation of a Common Receptor for Coxsackie B Viruses and Adenoviruses 2 and 5 , 1997, Science.

[154]  B. Harvey,et al.  Enhancement of in vivo adenovirus-mediated gene transfer and expression by prior depletion of tissue macrophages in the target organ , 1997, Journal of virology.

[155]  M. Hitt,et al.  Human adenovirus vectors for gene transfer into mammalian cells. , 1997, Advances in pharmacology.

[156]  R. Crystal,et al.  Innate immune mechanisms dominate elimination of adenoviral vectors following in vivo administration. , 1997, Human gene therapy.

[157]  M. Rudnicki,et al.  A helper-dependent adenovirus vector system: removal of helper virus by Cre-mediated excision of the viral packaging signal. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[158]  Marty W. Mayo,et al.  TNF- and Cancer Therapy-Induced Apoptosis: Potentiation by Inhibition of NF-κB , 1996, Science.

[159]  Seamus J. Martin,et al.  Suppression of TNF-α-Induced Apoptosis by NF-κB , 1996, Science.

[160]  D. Curiel,et al.  Targeted gene delivery by tropism-modified adenoviral vectors , 1996, Nature Biotechnology.

[161]  D. Brough,et al.  Adenovirus targeted to heparan-containing receptors increases its gene delivery efficiency to multiple cell types , 1996, Nature Biotechnology.

[162]  J. Gebert,et al.  Adenovirus-assisted lipofection: efficient in vitro gene transfer of luciferase and cytosine deaminase to human smooth muscle cells. , 1996, Atherosclerosis.

[163]  S. McGuire,et al.  Adenovirus-mediated gene transfer of herpes simplex virus thymidine kinase in an ascites model of human breast cancer. , 1996, Human gene therapy.

[164]  L. Leinwand,et al.  Adenovirus type 5 and 7 capsid chimera: fiber replacement alters receptor tropism without affecting primary immune neutralization epitopes , 1996, Journal of virology.

[165]  A. Houweling,et al.  Characterization of 911: a new helper cell line for the titration and propagation of early region 1-deleted adenoviral vectors. , 1996, Human gene therapy.

[166]  Xiang Gao,et al.  Cationic liposome-mediated gene transfer. , 1995, Gene therapy.

[167]  D. Curiel,et al.  Addition of a short peptide ligand to the adenovirus fiber protein. , 1995, Gene therapy.

[168]  J. Naftilan,et al.  Enhancement of liposome-mediated gene transfer into vascular tissue by replication deficient adenovirus. , 1995, Gene therapy.

[169]  G. Nemerow,et al.  Upregulation of integrins alpha v beta 3 and alpha v beta 5 on human monocytes and T lymphocytes facilitates adenovirus-mediated gene delivery , 1995, Journal of virology.

[170]  H. Ertl,et al.  Cellular and humoral immune responses to viral antigens create barriers to lung-directed gene therapy with recombinant adenoviruses , 1995, Journal of virology.

[171]  M. Kay,et al.  Strain related variations in adenovirally mediated transgene expression from mouse hepatocytes in vivo: comparisons between immunocompetent and immunodeficient inbred strains. , 1995, Gene therapy.

[172]  F. Graham,et al.  An efficient and flexible system for construction of adenovirus vectors with insertions or deletions in early regions 1 and 3. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[173]  R. Crystal,et al.  Administration of an adenovirus containing the human CFTR cDNA to the respiratory tract of individuals with cystic fibrosis , 1994, Nature Genetics.

[174]  J. Deisenhofer,et al.  Characterization of the knob domain of the adenovirus type 5 fiber protein expressed in Escherichia coli , 1994, Journal of virology.

[175]  P. Kitts,et al.  Cell-binding domain of adenovirus serotype 2 fiber , 1994, Journal of virology.

[176]  Gooding Lr.  Regulation of TNF-mediated cell death and inflammation by human adenoviruses. , 1994 .

[177]  Y. Inada,et al.  [7] Modification of proteins with polyethylene glycol derivatives , 1994 .

[178]  Ari Helenius,et al.  Stepwise dismantling of adenovirus 2 during entry into cells , 1993, Cell.

[179]  F. Graham,et al.  Packaging capacity and stability of human adenovirus type 5 vectors , 1993, Journal of virology.

[180]  G. Nemerow,et al.  Integrins α v β 3 and α v β 5 promote adenovirus internalization but not virus attachment , 1993, Cell.

[181]  B. Talbot,et al.  The orientation of the adenovirus fiber and its anchor domain identified through molecular mimicry. , 1989, Virology.

[182]  I. Pastan,et al.  Role of a low-pH environment in adenovirus enhancement of the toxicity of a Pseudomonas exotoxin-epidermal growth factor conjugate , 1984, Journal of virology.

[183]  N M Green,et al.  Evidence for a repeating cross‐beta sheet structure in the adenovirus fibre. , 1983, The EMBO journal.

[184]  A. Kirn,et al.  Interaction of viruses with sinusoidal cells. , 1982, Progress in liver diseases.

[185]  P. Jahrling,et al.  Comparisons among members of the Venezuelan encephalitis virus complex using hydroxylapatite column chromatography. , 1977, American journal of epidemiology.

[186]  F. Graham,et al.  Characteristics of a human cell line transformed by DNA from human adenovirus type 5. , 1977, The Journal of general virology.